Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8702 | 1226 | 26.2 | 49% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
1 | 4 | ECONOMICS//EDUCATION & EDUCATIONAL RESEARCH//PSYCHOL | 3876184 |
110 | 3 | PSYCHIATRY//SCHIZOPHRENIA//BIPOLAR DISORDER | 71389 |
2247 | 2 | TARDIVE DYSKINESIA//AKATHISIA//VACUOUS CHEWING MOVEMENTS | 4715 |
8702 | 1 | REDUCED HALOPERIDOL//BROMPERIDOL//REDUCED BROMPERIDOL | 1226 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | REDUCED HALOPERIDOL | authKW | 639762 | 3% | 76% | 34 |
2 | BROMPERIDOL | authKW | 591671 | 2% | 85% | 28 |
3 | REDUCED BROMPERIDOL | authKW | 174334 | 1% | 100% | 7 |
4 | HALOPERIDOL | authKW | 170123 | 11% | 5% | 135 |
5 | FLUPHENAZINE DECANOATE | authKW | 81348 | 1% | 47% | 7 |
6 | HALOPERIDOL METABOLITES | authKW | 79694 | 0% | 80% | 4 |
7 | HPTP | authKW | 77824 | 0% | 63% | 5 |
8 | BUTYROPHENONE TYPE AGENT | authKW | 74715 | 0% | 100% | 3 |
9 | HALOPERIDOL ANALOGS DERIVATIVES THERAPEUTIC USE | authKW | 74715 | 0% | 100% | 3 |
10 | HALOPERIDOL PYRIDINIUM | authKW | 74715 | 0% | 100% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Psychiatry | 16664 | 42% | 0% | 515 |
2 | Pharmacology & Pharmacy | 11655 | 56% | 0% | 692 |
3 | Medical Laboratory Technology | 1303 | 6% | 0% | 69 |
4 | Chemistry, Analytical | 1115 | 14% | 0% | 173 |
5 | Toxicology | 984 | 9% | 0% | 112 |
6 | Neurosciences | 832 | 17% | 0% | 211 |
7 | Chemistry, Medicinal | 271 | 5% | 0% | 63 |
8 | Clinical Neurology | 232 | 8% | 0% | 92 |
9 | Biochemical Research Methods | 219 | 5% | 0% | 66 |
10 | Psychology, Clinical | 130 | 3% | 0% | 34 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | HARVEY W PETERS STUDY PARKINSONS DIS DISORD | 37354 | 0% | 50% | 3 |
2 | CHEM HARVEY W PETERS | 24905 | 0% | 100% | 1 |
3 | CHIM ANALYT CONTROLE MEDICAMENTS | 24905 | 0% | 100% | 1 |
4 | CNS NEUROBIOL | 24905 | 0% | 100% | 1 |
5 | FOR UNGSZENTRUM IME | 24905 | 0% | 100% | 1 |
6 | LIFE SCI ATOM ENERGY CORP | 24905 | 0% | 100% | 1 |
7 | MARIE CURIE BELFAST | 24905 | 0% | 100% | 1 |
8 | MCLEAN MAILMAN PSYCHIAT S | 24905 | 0% | 100% | 1 |
9 | MED W LOS ANGELES VA MED BRENTWOOD | 24905 | 0% | 100% | 1 |
10 | MENTAL HLTH CLIN PSYCHOPHARMACOL UNIT | 24905 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY | 35336 | 5% | 2% | 62 |
2 | PHARMACOPSYCHIATRIA | 30371 | 1% | 10% | 12 |
3 | THERAPEUTIC DRUG MONITORING | 23951 | 5% | 2% | 60 |
4 | PSYCHOPHARMACOLOGY | 12805 | 6% | 1% | 79 |
5 | INTERNATIONAL PHARMACOPSYCHIATRY | 11183 | 1% | 6% | 7 |
6 | PSYCHOPHARMACOLOGY BULLETIN | 10871 | 2% | 2% | 28 |
7 | COMMUNICATIONS IN PSYCHOPHARMACOLOGY | 9424 | 0% | 8% | 5 |
8 | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | 6544 | 3% | 1% | 36 |
9 | PHARMACOPSYCHIATRY | 4939 | 2% | 1% | 20 |
10 | JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 4440 | 1% | 3% | 7 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | REDUCED HALOPERIDOL | 639762 | 3% | 76% | 34 | Search REDUCED+HALOPERIDOL | Search REDUCED+HALOPERIDOL |
2 | BROMPERIDOL | 591671 | 2% | 85% | 28 | Search BROMPERIDOL | Search BROMPERIDOL |
3 | REDUCED BROMPERIDOL | 174334 | 1% | 100% | 7 | Search REDUCED+BROMPERIDOL | Search REDUCED+BROMPERIDOL |
4 | HALOPERIDOL | 170123 | 11% | 5% | 135 | Search HALOPERIDOL | Search HALOPERIDOL |
5 | FLUPHENAZINE DECANOATE | 81348 | 1% | 47% | 7 | Search FLUPHENAZINE+DECANOATE | Search FLUPHENAZINE+DECANOATE |
6 | HALOPERIDOL METABOLITES | 79694 | 0% | 80% | 4 | Search HALOPERIDOL+METABOLITES | Search HALOPERIDOL+METABOLITES |
7 | HPTP | 77824 | 0% | 63% | 5 | Search HPTP | Search HPTP |
8 | BUTYROPHENONE TYPE AGENT | 74715 | 0% | 100% | 3 | Search BUTYROPHENONE+TYPE+AGENT | Search BUTYROPHENONE+TYPE+AGENT |
9 | HALOPERIDOL ANALOGS DERIVATIVES THERAPEUTIC USE | 74715 | 0% | 100% | 3 | Search HALOPERIDOL+ANALOGS+DERIVATIVES+THERAPEUTIC+USE | Search HALOPERIDOL+ANALOGS+DERIVATIVES+THERAPEUTIC+USE |
10 | HALOPERIDOL PYRIDINIUM | 74715 | 0% | 100% | 3 | Search HALOPERIDOL+PYRIDINIUM | Search HALOPERIDOL+PYRIDINIUM |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DAHL, SG , (1986) PLASMA-LEVEL MONITORING OF ANTIPSYCHOTIC-DRUGS CLINICAL UTILITY.CLINICAL PHARMACOKINETICS. VOL. 11. ISSUE 1. P. 36-61 | 91 | 91% | 106 |
2 | ULRICH, S , WURTHMANN, C , BROSZ, M , MEYER, FP , (1998) THE RELATIONSHIP BETWEEN SERUM CONCENTRATION AND THERAPEUTIC EFFECT OF HALOPERIDOL IN PATIENTS.CLINICAL PHARMACOKINETICS. VOL. 34. ISSUE 3. P. 227 -263 | 65 | 75% | 51 |
3 | FROEMMING, JS , LAM, YWF , JANN, MW , DAVIS, CM , (1989) PHARMACOKINETICS OF HALOPERIDOL.CLINICAL PHARMACOKINETICS. VOL. 17. ISSUE 6. P. 396-423 | 73 | 80% | 75 |
4 | JORGENSEN, A , (1986) METABOLISM AND PHARMACOKINETICS OF ANTIPSYCHOTIC-DRUGS.PROGRESS IN DRUG METABOLISM. VOL. 9. ISSUE . P. 111-174 | 64 | 84% | 54 |
5 | DEOLIVEIRA, IR , DARDENNES, RM , AMORIM, ES , DIQUET, B , DESENA, EP , MOREIRA, EC , DECASTROESILVA, EJ , PAYAN, C , FERMANIAN, J , MARCILIO, C , ET AL (1995) IS THERE A RELATIONSHIP BETWEEN ANTIPSYCHOTIC BLOOD-LEVELS AND THEIR CLINICAL EFFICACY - AN ANALYSIS OF STUDIES DESIGN AND METHODOLOGY.FUNDAMENTAL & CLINICAL PHARMACOLOGY. VOL. 9. ISSUE 5. P. 488-502 | 39 | 93% | 7 |
6 | FANG, J , MCKAY, G , SONG, JX , REMILLRD, A , LI, XM , MIDHA, K , (2001) IN VITRO CHARACTERIZATION OF THE METABOLISM OF HALOPERIDOL USING RECOMBINANT CYTOCHROME P450 ENZYMES AND HUMAN LIVER MICROSOMES.DRUG METABOLISM AND DISPOSITION. VOL. 29. ISSUE 12. P. 1638 -1643 | 37 | 74% | 41 |
7 | USUKI, E , VAN DER SCHYF, CJ , CASTAGNOLI, N , (1998) METABOLISM OF HALOPERIDOL AND ITS TETRAHYDROPYRIDINE DEHYDRATION PRODUCT HPTP.DRUG METABOLISM REVIEWS. VOL. 30. ISSUE 4. P. 809 -826 | 51 | 61% | 10 |
8 | SOTO, HAO , (1986) THEMES OF INTEREST - BLOOD-LEVELS OF THE NEUROLEPTICS.SALUD MENTAL. VOL. 9. ISSUE 4. P. 30-42 | 70 | 76% | 0 |
9 | MIDHA, KK , MARDER, SR , JAWORSKI, TJ , MCKAY, G , HUBBARD, JW , HAWES, EM , VANPUTTEN, T , WIRSHING, WC , ARAVAGIRI, M , (1993) CLINICAL PERSPECTIVES OF SOME NEUROLEPTICS THROUGH DEVELOPMENT AND APPLICATION OF THEIR ASSAYS.THERAPEUTIC DRUG MONITORING. VOL. 15. ISSUE 3. P. 179-189 | 35 | 92% | 6 |
10 | VANPUTTEN, T , MARDER, SR , WIRSHING, WC , ARAVAGIRI, M , CHABERT, N , (1991) NEUROLEPTIC PLASMA-LEVELS.SCHIZOPHRENIA BULLETIN. VOL. 17. ISSUE 2. P. 197-216 | 35 | 83% | 107 |
Classes with closest relation at Level 1 |